Life science reagent and service provider TriLink BioTechnologies has signed a non-exclusive license and supply agreement with Quantoom Biosciences for its CleanCap mRNA capping technology.
The technology will help Quantoom to accelerate the RNA proudction process, making mRNA-based therapeutics and vaccine more accessible to patients worldwide.
TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods.
Under the terms of the agreement, TriLink will supply its patented CleanCap technology for use in Quantoom's (sa)mRNA Ntensify production platform.
This will allow Quantoom's customers to effectively develop their (sa)mRNA drugs through all necessary clinical phases.
"Strengthening global health against infectious diseases requires strong industry partnerships," noted Becky Buzzeo, Chief Commercial Officer at Maravai, TriLink's parent company.
"We're excited for the Quantoom production platform to incorporate TriLink’s CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources."
TriLink's CleanCap technology debuted in 2017, and has since been used in the majority of all approved COVID-19 mRNA and saRNA vaccines.
“We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal," said José Castillo, CEO of Quantoom Biosciences.
"By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need," he concluded.